Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Vermeer is active.

Publication


Featured researches published by M. Vermeer.


Arthritis & Rheumatism | 2011

Implementation of a Treat-to-Target Strategy in Very Early Rheumatoid Arthritis Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Study

M. Vermeer; Hillechiena H. Kuper; M. Hoekstra; Cees J. Haagsma; Marcel D. Posthumus; Herman L. M. Brus; Piet L. C. M. van Riel; Mart A F J van de Laar

OBJECTIVE Clinical remission is the ultimate therapeutic goal in rheumatoid arthritis (RA). Although clinical trials have proven this to be a realistic goal, the concept of targeting at remission has not yet been implemented. The objective of this study was to develop, implement, and evaluate a treat-to-target strategy aimed at achieving remission in very early RA in daily clinical practice. METHODS Five hundred thirty-four patients with a clinical diagnosis of very early RA were included in the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Treatment adjustments were based on the Disease Activity Score in 28 joints (DAS28), aiming at a DAS28 of <2.6 (methotrexate, followed by the addition of sulfasalazine, and exchange of sulfasalazine with biologic agents in case of persistent disease activity). The primary outcome was disease activity after 6 months and 12 months of followup, according to the DAS28, the European League Against Rheumatism (EULAR) response criteria, and the modified American College of Rheumatology (ACR) remission criteria. Secondary outcomes were time to first DAS28 remission and outcome of radiography. RESULTS Six-month and 12-month followup data were available for 491 and 389 patients, respectively. At 6 months, 47.0% of patients achieved DAS28 remission, 57.6% had a good EULAR response, and 32.0% satisfied the ACR remission criteria. At 12 months, 58.1% of patients achieved DAS28 remission, 67.9% had a good EULAR response, and 46.4% achieved ACR remission. The median time to first remission was 25.3 weeks (interquartile range 13.0-52.0). The majority of patients did not have clinically relevant radiographic progression after 1 year. CONCLUSION The successful implementation of this treat-to-target strategy aiming at remission demonstrated that achieving remission in daily clinical practice is a realistic goal.


Annals of the Rheumatic Diseases | 2012

The new ACR / EULAR Definition of Remission in Rheumatoid Arthritis: Is the Patient Global Assessment Criterion too strict?

M. Vermeer; H.H. Kuper; Arie E. van der Bijl; H. Baan; M.D. Posthumus; H.L.M. Brus; P.L.C.M. van Riel; Mart A F J van de Laar


Rheumatology | 2010

Long-term Remission in Daily Clinical Practice: Excellent 2 Year Results with Treatment to Target in Ve3ry Early Theumatoid Arthritis, Results of the DREAM Remission Induction Cohort

M. Vermeer; H.H. Kuper; M. Hoekstra; H.J. Bernelot Moens; M.D. Posthumus; H.L.M. Brus; P.L.C.M. van Riel; Mart A F J van de Laar


EULAR 2010, Annual European Congress of Rheumatology | 2010

Is DAS28 Remission Good Enough? Disease Activity and Functionality in Rheumatoid Arthritis, Results of the DREAM Remission Induction Cohort

M. Vermeer; H.H. Kuper; M. Hoekstra; H.J. Bernelot Moens; P.L.C.M. van Riel; Mart A F J van de Laar


Arthritis & Rheumatism | 2010

Radiological progression in very early rheumatoid arthritis, results of the DREAM remission induction cohort

M. Vermeer; H.H. Kuper; M. Hoekstra; H.J. Bernelot Moens; P.L.C.M. van Riel; Mart A F J van de Laar


Annals of the Rheumatic Diseases | 2016

AB0196 The Relation between Baseline ACR/EULAR 2010 Classification Criteria and Structural Joint Damage Measured with Raad Score in Rheumatoid Arthritis

M. Vermeer; A. ter Avest; H.J. Bernelot Moens


Archive | 2012

Adherence aan een treat-to-target strategie in vroege rheumatoїde artritis: resultaten van het DREAM register inductie cohort

M. Vermeer; H.H. Kuper; H.J. Bernelot Moens; M. Hoekstra; Posthumus; P.L.C.M. van Riel; Mart A F J van de Laar


Archive | 2012

Adherence to a Treat-to-Target Strategy in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort

M. Vermeer; Ina H. Kuper; Hein J. Bernelot Moens; M. Hoekstra; Marcel D. Posthumus; P.L.C.M. van Riel; Mart A F J van de Laar


Archive | 2012

Cost-Effectiveness and Cost-Utility Analysis of Treat-to-Target Versus Usual Care in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Registry

M. Vermeer; Wietske Kievit; Ina H. Kuper; Louise Marie Antoinette Braakman-Jansen; Hein J. Bernelot Moens; T.R. Zijlstra; Alfons A. den Broeder; P.L.C.M. van Riel; Jaap Fransen; Mart A F J van de Laar


Archive | 2012

Kosteneffectiviteits- en kostenutiliteitsanalyse van treat-to-target versus reguliere zorg in vroege rheumatoїde artritis: resultaten van het DREAM register

M. Vermeer; Wietske Kievit; Ina H. Kuper; Louise Marie Antoinette Braakman-Jansen; H.J. Bernelot Moens; T.R. Zijlstra; A.A. den Broeder; P.L.C.M. van Riel; Mart A F J van de Laar

Collaboration


Dive into the M. Vermeer's collaboration.

Top Co-Authors

Avatar

Mart A F J van de Laar

Radboud University Nijmegen Medical Centre

View shared research outputs
Top Co-Authors

Avatar

M. Hoekstra

Medisch Spectrum Twente

View shared research outputs
Top Co-Authors

Avatar

P.L.C.M. van Riel

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

H.H. Kuper

Medisch Spectrum Twente

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ina H. Kuper

Medisch Spectrum Twente

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

H.L.M. Brus

Radboud University Nijmegen Medical Centre

View shared research outputs
Top Co-Authors

Avatar

Arie E. van der Bijl

Radboud University Nijmegen Medical Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge